Primary microcephaly Cell Models for Research

Primary microcephaly is a rare neurodevelopmental disorder characterized by a significantly reduced head circumference at birth (more than 2 standard deviations below the mean for age and sex) and non-progressive cognitive impairment. The global incidence is estimated at 1 in 30,000 to 1 in 250,000 live births, with higher prevalence in regions with consanguineous marriages. The condition results from genetic mutations affecting brain development, particularly cerebral cortical neurogenesis. There is no cure, and management is supportive. The clinical impact is lifelong, with affected individuals often requiring special care and educational support. Research significance lies in understanding fundamental mechanisms of brain development and neurogenesis, which can inform therapeutic strategies for a range of neurodevelopmental disorders.

Primary microcephaly is an ideal model for studying neurogenesis and cortical development. The disease is genetically heterogeneous, with over 25 genes identified, many of which are involved in centrosome function, DNA repair, and cell cycle regulation. Public datasets, such as those from the International Microcephaly Consortium and ClinVar, provide extensive genetic and clinical data. Open questions include the precise molecular pathways linking centrosome dysfunction to reduced neuronal output, and the potential for therapeutic intervention to stimulate neurogenesis. Gene-edited cell models enable functional validation of variants and exploration of pathogenic mechanisms.

Primary microcephaly is not a cancer, but it involves dysregulation of cell division and DNA damage response pathways. Key pathways include:

• • Centrosome and spindle assembly: Mutations in genes like ASPM, WDR62, and CENPJ disrupt centrosome function, leading to mitotic errors and premature neuronal differentiation.
• • DNA damage response: Genes such as BRCA1 and MCPH1 are involved in DNA repair; defects cause genomic instability and cell death.
• • Cell cycle regulation: Mutations in CDK5RAP2 and other genes affect the G2/M checkpoint, leading to reduced neural progenitor proliferation.
• • Apoptosis: Increased apoptosis of neural progenitors contributes to reduced brain size.

Data from TCGA and COSMIC are not directly applicable as these are germline mutations, but ClinVar and the Human Gene Mutation Database provide frequencies.

Key signaling networks involved in primary microcephaly include:

• • Wnt signaling: Regulates neural progenitor proliferation and differentiation. Mutations in microcephaly genes can disrupt Wnt pathway, leading to reduced progenitor pool.
• • Notch signaling: Controls cell fate decisions and neurogenesis. Dysregulation can cause premature differentiation.
• • PI3K/AKT/mTOR pathway: Involved in cell growth and survival. Aberrant signaling affects neuronal size and number.
• • DNA damage response network: ATM/ATR and p53 pathways are critical; defects lead to apoptosis and microcephaly.
• • Centrosome and mitotic spindle assembly: Key nodes include ASPM, WDR62, CDK5RAP2, and CENPJ, which interact with gamma-tubulin and other centrosomal proteins.

Organoids offer a 3D model that mimics early brain development, allowing study of neurogenesis and migration. Gene editing in organoids enables isogenic comparisons.

Animal models for primary microcephaly include:

• • Genetically engineered mouse models (GEMMs): Knockout mice for Aspm, Wdr62, Cdk5rap2, and Cepnj show microcephaly and neurogenesis defects.
• • Induced models: CRISPR-generated mutations in mice or rats to mimic patient variants.
• • Patient-derived xenografts (PDX) are not applicable for microcephaly as it is not a cancer, but brain organoids can be transplanted into mice for in vivo studies.
• • Non-human primate models are being developed but are limited by cost and ethics.

Gene-edited cell models are essential for functional studies. CRISPR-Cas9 technology allows creation of isogenic cell lines with specific mutations in microcephaly genes. For example:

• • ASPM knockout cell lines: Generated in SH-SY5Y or iPSC-derived neural progenitors to study centrosome function and neurogenesis.
• • WDR62 point mutation knock-in lines: Mimic patient mutations to assess impact on spindle orientation.
• • CDK5RAP2 knockout lines: Used to investigate centrosome maturation and cell cycle progression.

These models are commercially available from various sources, but we do not name specific companies. They are sequence-verified and can be used for drug screening, mechanistic studies, and validation of therapeutic targets.

Gene-edited cell lines enable functional validation of genetic variants. For example:

• • ASPM knockout in neural progenitors leads to reduced proliferation and premature differentiation, confirming its role in neurogenesis.
• • WDR62 knockout disrupts spindle orientation, leading to asymmetric division and reduced neuron number.
• • CRISPR screens can identify modifiers of microcephaly phenotypes, such as genes that rescue or exacerbate the defect.

Isogenic pairs (wild-type vs. mutant) are used for high-throughput drug screening. For instance:

• • Screen for compounds that enhance neural progenitor proliferation in ASPM knockout cells.
• • Test drugs that modulate DNA damage response in MCPH1 mutant cells.
• • Resistance modeling: Although not directly applicable, gene-edited cells can be used to study how cells adapt to mitotic inhibitors, relevant to cancer therapy.

CRISPR synthetic lethality screens can identify genes that are essential in microcephaly-mutant cells but not wild-type, revealing potential therapeutic targets. For example:

• • In ASPM knockout cells, screen for genes whose knockdown causes cell death, identifying vulnerabilities.
• • Biomarkers of disease progression can be discovered by comparing transcriptomes of edited vs. wild-type cells.